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ABSTRACT 
The cell surface protein CD44 is involved in diverse physiological processes, and its aberrant function is linked to 
various pathologies such as cancer, immune dysregulation, and fibrosis. The diversity of CD44 biological activity 
is partly conferred by the generation of distinct CD44 isoforms through alternative splicing. We identified an 
unexpected function for the ubiquitous hyaluronan-degrading enzyme, hyaluronidase 2 (HYAL2), as a regulator of 
CD44 splicing. Standard CD44 is associated with fibrotic disease, and its production is promoted through serine-
arginine–rich (SR) protein–mediated exon exclusion. HYAL2 nuclear translocation was stimulated by bone 
morphogenetic protein 7, which inhibits the myofibroblast phenotype. Nuclear HYAL2 displaced SR proteins 
from the spliceosome, thus enabling HYAL2, spliceosome components (U1 and U2 small nuclear 
ribonucleoproteins), and CD44 pre-mRNA to form a complex. This prevented double-exon splicing and facilitated 
the inclusion of CD44 exons 11 and 12, which promoted the accumulation of the antifibrotic CD44 isoform 
CD44v7/8 at the cell surface. These data demonstrate previously undescribed mechanisms regulating CD44 
alternative splicing events that are relevant to the regulation of cellular phenotypes in progressive fibrosis. 
 
INTRODUCTION 
Fibrosis underlies several organ-specific diseases and contributes to the burden of chronic diseases, 
such as chronic kidney disease, liver cirrhosis, pulmonary fibrosis, cardiac failure, and degenerative joint 
disease. Myofibroblasts are the principal effector cells driving fibrosis, and their accumulation in tissues is a 
fundamental feature of fibrosis (1). These cells are derived from the differentiation of fibroblasts, fibrocytes, 
or epithelial cells under the influence of circulating profibrotic growth factors such as transforming growth 
factor–b1 (TGF-b1) (2). Therefore, prevention or reversal of the myofibroblast phenotype is an attractive 
therapeutic approach to the treatment of fibrotic disease. We have previously shown that this is achievable 
through stimulation of myofibroblasts with bone morphogenetic protein 7 (BMP7) (3). However, BMP7 
itself is not viable for therapy due to its demonstrated ability to promote bone metastasis in osteotropic 
cancers and its role in promoting ectopic bone formation (4). 
Hyaluronan (HA) is a matrix glycosaminoglycan that influences many cellular functions and is 
implicated in numerous biological processes and disease states. The work from our laboratories 
demonstrates that establishment and maintenance of the myofibroblast phenotype are dependent on TGF-b1–
driven promotion of an HA pericellular matrix, the HA coat (5). CD44 is the principal cell surface HA 
receptor. It is broadly distributed in tissues and is involved in diverse physiological processes. Its aberrant 
function is implicated widely in pathology, with key roles in cancer, inflammation, immune dysregulation, 
vascular disease, fibrosis, and wound healing (6). CD44 is encoded by a single gene consisting of 19 exons 
and displays considerable protein diversity conferred partly by the ability of these exons to undergo 
alternative splicing for generating multiple CD44 variant (CD44v) isoforms (7, 8). Exons 1 to 5, 15 to 17, 
and 19 are constant and present in all alternatively spliced CD44 mRNA species. These exons encode the 
extracellular N-terminal domain, the transmembrane domain, and the cytoplasmic region, all of which are 
present in every CD44 isoform. The presence of exons 6 to 14 varies between isoforms, resulting in the 
multitude of CD44v presently documented. Exon 18 is removed before translation inmost isoforms due to its 
inclusion of an early stop codon. One isoform described to contain exon 18 is a small, truncated form of 
CD44 with no intracellular signaling domain, the function of which remains unclear (9). Standard CD44 
(CD44s) is the most abundant CD44 isoform with a predicted molecular mass of 85 to 90 kDa. CD44s only 
contains regions encoded by exons 1 to 5, 15 to 17, and 19. All other variants have this overall pattern but 
include additional amino acid sequences derived from various combinations of exons 6 to14. These 
sequences form the extracellular stem structure, resulting in receptor variants of different sizes (Fig. 1, A to 
B). TGF-b1–driven HA coat assembly and myofibroblast differentiation is dependent on the 85- to 90-kDa 
CD44s, which is processed into a 347 amino acid sequence that colocalizes with the epidermal growth factor 
receptor (EGFR) within cholesterol-rich lipid rafts (10). By contrast, BMP7-driven HA coat dissolution and 
prevention or reversal of the myofibroblast phenotype depend on the presence of the 190-kDa variant 
isoform CD44v7/8, which is processed into a 424 amino acid–containing protein and so named because this 
isoform is encoded from CD44 pre-mRNA that contains the two variable region exons, 11 and 12 (Fig. 1C). 
These exons encode an extracellular stem region, which is thought to convey an additional glycosylation site 
and additional function to the CD44v7/8 protein (3). Factors that govern the production of the pro- or 
antifibrotic CD44 isoforms are unclear; therefore, we investigated the regulation of CD44 alternative 
splicing under antifibrotic conditions. Here, we present a mechanism that controls CD44 alternative splicing 
events relevant to the determination of cell phenotype. 
The breakdown of HA is mediated by the hyaluronidase (HYAL) group of enzymes. HYAL1 and 
HYAL2 are the most abundant HYALs in vertebrates. HYAL2 is present in many tissues, and its biological 
importance has been demonstrated in studies of Hyal2 knockout mice, which display skeletal abnormalities, 
cardiopulmonary dysfunction, hematological anomalies, and exacerbated renal inflammation and fibrosis 
(11, 12). Previously, HYAL2 has been identified within lysosomes, wherein the acidic environment is 
optimal for HYAL activity. In addition, HYAL2 has been identified as a cell membrane-anchored protein, 
where it only has weak enzymatic activity (13–15). Several reports also indicate that a large proportion of 
HYAL2 in tissues may be enzymatically inactive, so its cellular function in context of cellular localization is 
unclear (16–18). Here, we identify an unexpected nonenzymatic function for HYAL2 that can potentially 
explain its broad biological effects. We identify HYAL2 as a key regulator of pre-mRNA splicing that 
dictates the production of CD44v isoforms. 
 
RESULTS 
Fluorescent bichromatic minigene reporters indicate BMP7-regulated CD44 alterative splicing 
The CD44s and CD44v7/8 proteins are produced from divergent transcripts that are generated by 
alternative splicing of theCD44 pre-mRNA (Fig. 1, A to C). In addition to the standard exons (exons 1 to 5, 
15 to 17, and 19), the CD44v7 variant isoform includes exon 11 [132 base pairs (bp)], and the CD44v8 
isoform includes exon 12 (102 bp), whereas the CD44v7/8 variant isoform includes both exons 11 and 12 
(234 bp). Therefore, to better understand alternative splicing resulting in CD44v7/8, we developed two 
fluorescent bichromatic minigene reporters to investigate splicing activity surrounding the variable exons. 
The two minigene reporters were used to determine what factors influenced induction of CD44s versus 
CD44v7 or CD44v8 (fig. S1, A and B). The minigene reporter plasmids contain a bichromatic reporter that 
produces either red fluorescent protein (dsRED) or enhanced green fluorescent protein (EGFP), depending 
on exon inclusion or exclusion, respectively. These pRG6 minigenes use the original construct backbone 
developed by Orengo et al. (19). Exon 11 and flanking introns 10 and 11 (pRG6-CD44v7) or exon 12 and 
flanking introns 11 and 12 (pRG6-CD44v8) were cloned into the minigene reporters. The presence of red 
fluorescence indicates the inclusion of the alternatively expressed exon 11 (pRG6-CD44v7) or exon 12 
(pRG6-CD44v8), indicating conditions that favor increased CD44v7/8 production. Green fluorescence 
indicates the exclusion of the exons, indicating conditions that favor CD44s production. Stimulating 
proximal tubular epithelial cell (PTEC) (HK-2) cells expressing either pRG6-CD44v7 or pRG6-CD44v8 
with BMP7 attenuated green fluorescence and increased red fluorescence (fig. S1, C and D), confirming 
BMP7 as an important inducer of alternative splicing that favors CD44v7/8 production. 
 
CD44s expression is dependent on SRSF2 and SRSF5 
An in silico analysis of intronic sequences surrounding exons that are included in CD44v7 and v8 
revealed recognition sites for SR splicing factor (SRSF) proteins (fig. S2). Threshold scores for SRSF2 and 
SRSF5 binding sites were prominent, suggesting a role for these proteins in CD44 alternative splicing (tables 
S1 and S2). We transfected PTEC (HK-2) lines stably expressing the reporter pRG6-CD44v7 or pRG6-
CD44v8 with constructs encoding small interfering RNAs (siRNAs) directed against SRSF2 or SRSF5 (Fig. 
2,AandB). Protein knockdown was also confirmed (fig. S3). Cells transfected with scrambled controls 
demonstrated only green fluorescence, indicating that exons 11 or 12were spliced out to generate CD44v7 or 
CD44v8, respectively. Scrambled controls stimulated with BMP7 showed reduced green and increased red 
fluorescence, indicating appropriate inclusion of exon 11 (CD44v7) or exon 12 (CD44v8) and suggesting 
enhanced CD44v7/8 expression. SRSF2 knockdown in unstimulated cells increased red and attenuated green 
fluorescence, mimicking the effects of BMP7. This effect was more pronounced with knockdown of SRSF5 
in unstimulated cells, which fully mimicked BMP7 conditions, abrogating green and promoting red 
fluorescence. Thus, both splice factors were required for exons 11 and 12 skipping; however, the effect of 
SRSF5 knockdown was more pronounced. BMP7 stimulation of cells with SRSF2 knockdown caused a shift 
in fluorescence that did not occur in BMP7-stimulated cells with SRSF5 knockdown, which also highlighted 
the particular importance of SRSF5. We assessed the direct effects on CD44s and CD44v7/8 mRNA 
expression by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). Successful 
SRSF2 mRNA knockdown was verified (Fig. 2C). CD44s mRNA expression showed no significant 
attenuation after SRSF2 knockdown (Fig. 2D), we found that SRSF2 knockdown enhanced CD44v7/8 
mRNA expression, implicating SRSF2 in promoting CD44s splicing (Fig. 2E). After verifying SRSF5 
knockdown (Fig. 2F), we found that SRSF5 knockdown significantly attenuated CD44s mRNA expression 
(Fig. 2G) and enhanced CD44v7/8 expression (Fig. 2H). These data indicate a role for SRSF2 and SRSF5 in 
preventing alternative splicing to generate CD44v7/8 and a role for SRSF5 in driving CD44s mRNA 
expression. 
 
Nuclear HYAL2 interacts with CD44 pre-mRNA to promote CD44v7/8 alternative splicing 
We previously demonstrated that BMP7 increased HYAL2 mRNA expression and that HYAL2 
was critical in mediating BMP7-driven prevention or reversal of the myofibroblast phenotype (3). Here, we 
investigated the potential role of HYAL2 on the regulation of CD44 alternative splicing. We first determined 
whether BMP7 influenced HYAL2 cellular localization. Confocal microscopy demonstrated increased 
nuclear accumulation of HYAL2 in primary human lung fibroblasts, in response to BMP7 treatment (Fig. 
3A). This was confirmed by immunoblotting of nuclear extracts, which showed reduced cytoplasmic and 
increased nuclear HYAL2 protein after BMP7 treatment (Fig. 3, B and C). Nuclear HYAL2 exhibited a 
slightly reduced molecular weight compared to cytoplasmic HYAL2 (~4 to 5 kDa smaller), suggesting that 
the protein undergoes cytoplasmic cleavage before nuclear translocation. siRNA-mediated knockdown of 
HYAL2 strongly reduced, but did not entirely eliminate, both cytoplasmic and nuclear HYAL2 abundance. 
Subsequent RNA immunoprecipitation (RIP) assays using antibodies directed against HYAL2 were used to 
assess the potential of HYAL2 to bind to and interact with mRNA or pre-mRNA. RIP assays revealed 
binding interactions between HYAL2 and CD44 intron 10 under all conditions tested and 
betweenHYAL2andCD44 intron 12 afterBMP7stimulation (Fig. 3D). These intronic sequences flank CD44 
exons 11 and 12, which are included in the CD44v7 and CD44v8 pre-mRNA transcripts, respectively, in 
addition to the CD44s exons. 
To determine the effects ofHYAL2 on CD44v7/8 mRNA expression and protein abundance, we 
used siRNAs to knock downHYAL2 (Fig. 4A) in primary human lung fibroblasts and measured the 
abundance of the transcripts and proteins by qRT-PCR, Western blotting, and fluorescence microscopy. 
HYAL2 knockdown induced a small increase in CD44s mRNA expression in untreated fibroblasts (Fig. 4B) 
and attenuated both basal and BMP7-driven expression of CD44v7/8 (Fig. 4C), indicating that, in the 
absence of HYAL2, CD44 pre-mRNA did not undergo alternative splicing to generate CD44v7/8 mRNA. At 
the protein level, HYAL2 knockdown reduced the abundance of CD44v7/8 but did not influence the 
abundance of CD44s (Fig. 4, D and E). Knocking down HYAL2 in PTEC (HK-2) lines, stably expressing 
the minigene reporter pRG6-CD44v7 or pRG6-CD44v8 (Fig. 4F), increased CD44s expression in 
untransfected, untreated cells and in pRG6-CD44v7–expressing cells that were treated with BMP7 (Fig. 4G). 
HYAL2 knockdown also prevented the BMP7-induced increase in CD44v7/8 expression in untransfected, 
pRG6-CD44v7–expressing, and pRG6-CD44v8–expressing cells (Fig. 4H). Fluorescence microscopy 
verified these results. After HYAL2 knockdown, BMP7 treatment no longer promoted the shift from green 
fluorescence to red. Instead, HYAL2 knockdown mimicked the results seen in unstimulated cells (Fig. 4, I 
and J), confirming HYAL2 as a critical regulator of CD44v7/8 alternative splicing. 
To identify proteins that interact with HYAL2, we performed mass spectrometry (MS) on proteins 
that coimmunoprecipiated with HYAL2 from primary human lung fibroblast nuclear extracts. We identified 
13 candidate proteins that interacted with nuclearHYAL2 and could potentially function with HYAL2 to 
affect CD44 alternative splicing (table S3). These candidates included proteins involved in nuclear 
trafficking (nuclear pore complex trafficking protein and spectrin), alternative splicing (zinc finger matrin-
type protein 2 and RNA binding protein), and DNA or RNA processing (elongation factor of translation and 
translation initiation factors). Identification of these putative binding partners suggests that HYAL2 might 
influence splicing of other target genes in addition to CD44. However, we detected no association between 
HYAL2 and SRSF proteins using this method. In silico analysis of theHYAL2 peptide sequence 
demonstrated a putative bipartite nuclear localization signal (NLS) motif 34 amino acids downstream from 
the designated HYAL2 active site (table S4). This suggests that HYAL2 may undergo nuclear trafficking by 
association with importins (20). Furthermore, four putative binding sites for DNA and RNA nucleotide 
sequences were located downstream of the NLS motif of HYAL2, and one was located within the HYAL2 
EGF-like domain, near the C terminus. 
 
HYAL2 displaces SRSF5 from CD44 pre-mRNA and the early spliceosome, thus preventing SRSF5-
spliceosome–mediated exon 11 and exon 12 exclusion 
HYAL2 and SRSF proteins were both implicated in CD44 alternative splicing but with opposing 
effects. Direct interactions between HYAL2 and SRSFs were directly investigated, but 
coimmunoprecipitation demonstrated no binding between HYAL2 and SRSF2 or SRSF5 (Fig. 5A). We 
performed RIP assays in primary human lung fibroblasts using antibodies directed against SRSF2 or SRSF5 
in the presence or absence of siRNAtargetingHYAL2. RIP assays demonstrated no association of SRSF2 
with CD44 pre-mRNA, because the enrichment was comparable to RIP negative control immunoglobulin G 
(IgG) (fig. S4), which suggested that the role of SRSF2 in CD44 alternative splicing was not through direct 
SRSF2-CD44 pre-mRNA associations. By contrast, SRSF5 exhibited high fold enrichment and associations 
with CD44 introns 10 and 12 in unstimulated cells, and BMP7 stimulation attenuated these interactions. 
HYAL2 knockdown prevented BMP7 treatment from attenuating the interactions between SRSF5 and CD44 
introns, indicating that the BMP7 response was HYAL2-dependent (Fig. 5B). Thus, HYAL2 appeared to 
displace SRSF5 from CD44 intron 12 splice sites, thereby preventing SRSF5-mediated exons 11 and 12 
skipping. Subsequent experiments demonstrated that HYAL2 knockdown increased SRSF2 and SRSF5 
mRNA expression (Fig. 5, C and D), suggesting a role for HYAL2 in the transcriptional repression of these 
splicing factors. 
In silico analysis of intronic sequences surrounding exons 11 and 12 identified 3′ and 5′ U2-
acceptor sites on introns 10, 11, and 12 as regions of putative spliceosome activity (fig. S2). Consequently, 
we performed RIP assays using antibodies recognizing HYAL2, SRSF2, or SRSF5 to assess the association 
of these proteins with several spliceosome components: U1, U2, U4, and U6 small nuclear RNAs (snRNAs). 
BMP7 promoted strong interactions between HYAL2 and the U1 and U2 snRNAs (U1/U2), which comprise 
the early spliceosome (Fig. 5E). HYAL2 knockdown significantly enhanced the association between SRSF2 
and U1/U2 and between SRSF2 and U4 and U6 (U4/U6), suggesting HYAL2 involvement in the regulation 
of SRSF2-spliceosome interactions (Fig. 5F). Similarly, SRSF5 demonstrated strong interactions with the 
snRNA components of early (U1/U2) and mature (U4/U6) spliceosomes in unstimulated cells, and BMP7 
significantly reduced these associations (Fig. 5G). HYAL2 knockdown prevented the BMP7-mediated 
attenuation of SRSF5-spliceosome interactions, indicating that HYAL2 was essential for SRSF5-
spliceosome dissociation. Hence, HYAL2 prevents mature spliceosome formation and splicing initiation, 
thus favoring CD44v7/8 expression. In concert, our data support a model wherein SRSF2 and SRSF5 bind to 
intronic regions of CD44 pre-mRNAs to promote variant exon exclusion, thus enhancing CD44s expression. 
HYAL2 displaces SRSF2 and SRSF5 from CD44 pre-mRNA intronic regions and from the spliceosome 
complex to promote exons 11 or 12 inclusion, thus enhancing CD44v7/8 mRNA expression and protein 
production (Fig. 6, A to C).  
DISCUSSION 
The roles of CD44v isoforms have been widely studied in cancer, with different isoforms shown to 
have distinct and sometimes opposing functions (7). However, the relevance of these isoforms to the 
promotion and prevention of fibrotic disorders has only begun to be appreciated. An understanding of 
cellular and molecular mechanisms that regulate the switch from deleterious (profibrotic) to protective 
(antifibrotic) CD44vs may therefore be an important determinant of fibrosis outcomes. Previous studies 
investigated regulators of CD44 alternative splicing in the context of cancer biology, but limited information 
is available regarding CD44 alternative splicing in fibrosis. Induction of type III epithelial-mesenchymal 
transition (EMT) in cancer, which is similar to type II EMT in fibrosis, is associated with a shift in CD44 
isoforms from variants to the standard (CD44s) isoform. Epithelial splicing regulatory proteins, argonaute-
mediated histone modifications, Src associated mitosis 68 kDa (Sam68), and transformer 2 b homolog have 
been identified as regulators of CD44 splicing (8, 21, 22), mainly in cancers. In addition, Sam68 is activated 
by Ras and downstream of Ras and extracellular signal–regulated kinases 1 and 2 (ERK1/2) signaling, and 
influences alternative splicing to result in increased expression of CD44v5, in which exon 9 is included (8). 
Ras and ERK1/2 are also important regulators of profibrotic cellular signaling pathways, suggesting that 
CD44v5, in addition to CD44s, may favor the generation of profibrotic cellular phenotypes. Here, we show 
that HYAL2, SRSF2, and SRSF5 play integral roles in controlling cell systems relevant to fibrosis and type 
II EMT by acting as CD44 splicing regulators. Although SRSF proteins are commonly thought to enhance 
exon inclusion, the literature indicates that their position relative to a 5′ splice site determines whether they 
activate or repress splicing (23). 
The presence of the enzyme HYAL2 in the nucleus was unexpectedly able to counteract the effects 
of SRSF5 in CD44 pre-mRNA splicing and played a key role in regulating the production of SRSF2 and its 
interactions with CD44 pre-mRNA. All HYAL2 activities have been previously ascribed to its role in HA 
catabolism. Murine studies demonstrated that extracellular HA accumulated in Hyal2-null tissues, indicating 
a clear role for HYAL2 in HA degradation (24). However, HYAL2 exhibits very low enzymatic activity 
compared to other HYALs and requires a pH of 3.8 for optimal activity (25). Therefore, why an enzyme that 
functions optimally in acidic pH should be present in tissues with higher pH values or what the purpose of 
nonenzymatically active HYAL2 may be has been unclear and raised the possibility of noncatabolic 
functions for this protein. It was proposed that cofactors mightmodulateHYAL2 activity to convert it into a 
more active enzyme at higher pH. It has been reported that the ability of HYAL2 to promote acidification of 
the cellular microenvironment requires the presence of the Na+/H+ exchanger NHE1 (26). However, there are 
reports that HYAL2 has additional functions beyond its role in HA catabolism. Duterme et al. (17) found 
that HYAL2 functions as a co-receptor forCD44, Liu et al. (18) identifiedHYAL2 as a viral cell entry 
receptor, and Hsu et al. (27) showed that cell surface HYAL2 formed a complex with TGF-b1 and WW 
domain–containing oxidoreductase (WWOX). In relevance to fibrosis, Colombaro et al. (12) demonstrated 
that knocking out Hyal2 in mice exacerbates renal fibrosis in response to ischaemia-reperfusion injury. In 
previous studies, we have shown that cells deficient in HYAL2 are no longer resistant to BMP7-driven 
prevention and reversal of the myofibroblast phenotype (3). In extension of our previous findings, this study 
presents a previously undiscovered nonenzymatic role for HYAL2 in regulating alternative splicing that is 
relevant to the cell biology of fibrosis. 
The data presented here support a model wherein SRSF5 binds to putative 3′ and 5′ intronic 
splicing sites within introns 10 and 11 of CD44 pre-mRNA (Fig. 6A). SRSF5 binding to these splice sites 
recruits snRNPs, leading to the formation of mature spliceosomes (U1/U2 and U4/U6.U5). This promotes 
variant exon exclusion by means of double exon skipping alternative splicing. SRSF2 does not bind to this 
region of CD44 pre-mRNA but associates with U1/U2 snRNPs and, according to previous literature (28), 
functions in promoting the efficacy of U1/U2 splicing initiation and mature tri-snRNP (U4/U6.U5) binding, 
thereby promoting the production of CD44s transcripts that are translated into CD44sprotein (Fig. 6B). The 
presence of CD44s on the cell surface promotes HA coat maintenance, which facilitates myofibroblast 
differentiation. BMP7 stimulation promotes translocation of HYAL2 to the nucleus, where it displaces 
SRSF5 from the early spliceosome (U1/U2) and prevents the SRSF5-mediated formation of mature 
spliceosomes. HYAL2 also acts at the intronic splice site, where it prevents SRSF5 from binding to intron 
12 of theCD44 pre-mRNA. This impairs recruitment of the spliceosome to CD44 pre-mRNA, preventing the 
double-exon skipping splicing event and resulting in the inclusion of exons 11 and 12 (Fig. 6C). CD44v7/8 
is subsequently produced and present at the cell surface, where it promotes HA coat internalization, thus 
blocking myofibroblast differentiation. Although the data demonstrate a clear mechanism for the 
displacement of SRSF5 by HYAL2, the influence of HYAL2 on SRSF2 is less clear. We postulate that 
HYAL2 inhibits SRSF2 transcription, thus favoring the production of CD44v7/8 by reducing alternative 
splicing activity through attenuation of spliceosome recruitment to the CD44 pre-mRNA, specifically around 
exons 11 and 12. Therefore, stimuli resulting in HYAL2 attenuation would reduce nuclear HYAL2, enhance 
SRSF2 abundance, and lead to its increased availability and interactions with early and mature spliceosome 
snRNPs, promoting CD44s expression. 
HYAL2 functionality is considerably more complex than was initially envisaged after its discovery 
as a catabolic enzyme involved in HA degradation. Although we have not directly tested whether the 
catalytic activity of HYAL2 is dispensable in influencing CD44 splicing, given that HYAL’s only known 
substrate is HA, any function dependent on catalytic activity would likely require the presence of HA within 
the nucleus. Although this report demonstrates an important role for HYAL2 in CD44 alternative splicing, 
the presence of nuclear HYAL2 and its interaction with regulators of DNA and RNA processing suggest that 
HYAL2 may have as-yet-undiscovered roles in regulation of gene expression. 
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MATERIALS AND METHODS 
Materials 
All reagents were purchased from Sigma-Aldrich or Life Technologies and Invitrogen unless otherwise 
stated. Reverse transcription reagents, siRNA transfection reagents, and qRT-PCR primers and reagents 
were purchased from Invitrogen and Applied Biosystems. Recombinant human (rh) BMP7 was from Merck 
Millipore.  
 
Cell culture 
Primary human lung fibroblasts and transformed human renal PTEC (HK-2) were used in all experiments. 
Primary human lung fibroblasts (AG02262) were purchased from Coriell Cell Repositories (Coriell Institute 
for Medical Research). The cells were cultured in Dulbecco’s modified Eagle’smedium (DMEM)/Ham’s 
F12 containing 5mMglucose, 2 mML-glutamine, penicillin (100 U/ml), streptomycin (100 mg/ml), and 
supplemented with 10% fetal bovine serum (FBS; Biological Industries Ltd.). For experiments requiring 
stable expression of the minigene reporters, transformed human PTECs (CRL-2190; American Type Culture 
Collection) were used. PTECs were the HK-2 cell line, immortalized by transduction with HPV-16 E6/E7 
genes (29), and were cultured in DMEM/Ham’s F12 (Life Technologies) supplemented with 10% FBS (Sera 
Laboratories International Ltd.) containing 5mMglucose, 2mML-glutamine, transferrin (5 mg/ml), sodium 
selenite (5 ng/ml), and hydrocortisone (0.4 mg/ml) (Sigma-Aldrich). All cells were maintained at 37°C in a 
humidified incubator in an atmosphere of 5% CO2, and fresh growth medium was added to the cells every 3 
to 4 days until the cells were ready for experimentation. Cells were growth-arrested in serum free medium 
for 48 hours before use in all experiments, and all experiments were performed under serum-free conditions 
unless otherwise stated. All experiments using fibroblasts were undertaken using cells at passage 6 to 10. 
Fibroblasts and PTECs (HK-2s) were stimulated with BMP7 (400 ng/ml) for 72 hours according to previous 
protocols (3).  
 
Bichromatic pRG6 minigene reporter design and generation of stable cell lines 
The pRG6-CD44v7 and pRG6-CD44v8 plasmids were derived from the pRG6-FGFR2 minigene plasmid 
(30). CD44 exon 11 (v7) or CD44 exon 12 (v8), together with corresponding upstream and downstream 
introns, was amplified from genomic DNA (gDNA) using specific primers and introduced into the plasmids 
at the XbaI/AgeI cloning sites using In-Fusion HD Cloning kits (Clontech, Takara Bio), according to the 
manufacturer’s protocol. Two plasmid were generated: pRG6-CD44v7 and pRG6-CD44v8. Plasmids were 
transfected into PTECs (HK-2s) using Lipofectamine LTX reagent, according to protocol (Invitrogen). After 
confluence, cells were lifted with a 0.1% EDTA solution and flow-sorted, gated on EGFP expression, into 
fresh cultures dishes using an LSRFortessa cell sorter (BD Biosciences). Specific primer pairs were designed 
and purchased (Applied Biosystems) to amplify between the artificial start exon of pRG6 and the EGFP 
domain to confirm minigene function (see fig. S1). Fragments were amplified using the Phusion High-
Fidelity DNA polymerase system (New England Biolabs). Briefly, 4 ml of 5Å~High-Fidelity buffer, 0.4 ml 
of deoxynucleotide triphosphate mix, 1 ml of 10 mM forward primer, 1 ml of 10 mM reverse primer, 0.2 ml 
of Phusion DNA polymerase, 10 ng of cDNA template, and distilled H2O were added to a final volume of 20 
ml. Samples were PCR-amplified with the following thermocycling conditions: 98°C for 30 s, 35 cycles of 
98°C for 10 s, 65°C for 30 s, and 72°C for 30 s. This was followed by a final extension at 72°C for 10 min. 
The resultant PCR products were run on 1% agarose gels by flatbed electrophoresis. These sub-line cultures 
were grown to confluence and flow-sorted once more to ensure cell cultures with stable expression of each 
plasmid (pRG6-CD44v7 and pRG6-CD44v8). Stable cell sub-lines were grown on eight-well glass chamber 
slides and were fixed with 4% paraformaldehyde after treatment and mounted for visualization using 
fluorescent light microscopy. Nuclei were stained using VECTASHIELD DAPI (Vector Laboratories). 
 
Immunocytochemistry 
Cells were grown to 70% confluence in eight-well glass chamber slides (Merck Millipore). The culture 
medium was removed, and the cells were washed with sterile phosphate-buffered saline (PBS) before 
fixation in 4% paraformaldehyde for 10 min at room temperature. After fixation, cells were permeabilized 
with 0.1% (v/v) Triton X-100 in PBS for 10 min at room temperature. Slides were blocked with 1% bovine 
serum albumin (BSA) for 1 hour before a further washing step with 0.1% (w/v) BSA in PBS. Subsequently, 
the slides were incubated with rabbit antibodies recognizing human HYAL2 primary antibody (Atlas 
antibodies by Sigma-Aldrich) diluted in 0.1% BSA-PBS for 2 hours at room temperature. After a further 
washing step, slides were incubated with goat antibodies recognizing rabbit Alexa Fluor 595–conjugated 
secondary antibody (Invitrogen) in 0.1% BSA-PBS for 1 hour at room temperature in the dark. Cells were 
then mounted and analyzed by confocal fluorescent microscopy. 
 
siRNA transfection 
Transient transfections of fibroblasts and PTECs (HK-2s) were carried out with specific siRNA nucleotides 
(Applied Biosystems) targeting HYAL2, SRSF2, or SRSF5 mRNAs for knockdown (siHYAL ID s427, 
s428; siSRSF2 ID s12729, s12730; siSRSF5 ID s12738, s12739). Transfection was carried out using 
Lipofectamine 2000 transfection reagent (Invitrogen) in accordance with the manufacturer’s protocol, and 
the two siRNAs for each target were cotransfected to achieve optimal knockdown. Briefly, cells were grown 
to 70% confluence in antibiotic free medium in either 35-mm dishes or eight-well glass chamber slides. 
Transfection reagent (2% v/v) was diluted in Opti-MEM reduced growth medium (Gibco) and left to 
incubate for 5 min at room temperature. The specific siRNA oligonucleotides were diluted in Opti-MEM 
reduced growth medium to achieve a final concentration of 30 nM per siRNA. The transfection agent and 
siRNA mixtures were then combined and incubated at room temperature for an additional 20 min. The 
newly formed transfection complexes were subsequently added to the cells and were incubated at 37°C with 
5%CO2 for 24 hours in serum-free medium before experimentation. As a control, cells were transfected with 
negative control siRNAs (scrambled sequences that bear no homology to the human genome) (Silencer 
Select Negative Control No. 1 and No. 2; Applied Biosystems). 
 
Real-time qRT-PCR 
Real-time qRT-PCR was used to assess HYAL2, CD44s, CD44v7/8, SRSF2, and SRSF5 mRNA 
expressions. Primers and probes for these genes were either commercially available or designed (table S5) 
and purchased from Applied Biosystems. The cells were grown in 35-mm dishes and washed with PBS 
before lysis with TRI-Reagent and RNA purification according to the manufacturer’s protocol. Reverse 
transcription was carried out using the high-capacity cDNA reverse transcription kit according to the 
manufacturer’s protocol (Applied Biosystems). This kit uses the random primer method for initiating cDNA 
synthesis. As a negative control, reverse transcription was carried out with sterile H2O replacing the RNA 
sample. For commercially purchased TaqMan primers and probes (Applied Biosystems), qRT-PCR was 
carried out using the ViiA7 real-time qPCR system from Applied Biosystems in a final volume of 20 ml per 
sample as follows: 1 ml of reverse transcription product, 1 ml of target gene primers and probe, 10 ml of 
TaqMan Fast Universal PCR MasterMix, and 8 ml of sterile RNase free water. Amplification was carried 
out using a cycle of 95°C for 1 s and 60°C for 20 s for 40 cycles. qRT-PCR was simultaneously performed 
for ribosomal RNA (18S rRNA) as a standard reference gene. For assessment of custom primer pairs, 
designed and purchased from Invitrogen, qRT-PCR was carried out with the ViiA7 real-time qPCR system 
from Applied Biosystems in a final volume of 20 ml per sample as follows: 1 ml of reverse transcription 
product, 0.6 ml of 10 mM target gene forward primer and 0.6 ml of 10 mM target gene reverse primer, 10 ml 
of Power SYBR Green Master Mix, and 7.8 ml of sterile RNase-free water. Amplification used a cycle of 
95°C for 15 s and 60°C for 1 min for 40 cycles, followed by a melt-curve stage at 95°C for 15 s, 60°C for 1 
min, and a final step of 95°C for 15 s. qRT-PCR was simultaneously performed for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA expression (custom primers designed and purchased from 
Applied Biosystems) as a standard reference gene. As a negative control, qRT-PCRwas performed with 
sterileH2O, replacing the cDNA sample. The comparative CT method was used for relative quantification of 
gene expression. The CT (threshold cycle where amplification is in the linear range of the amplification 
curve) for the standard reference gene (rRNA/GAPDH) was subtracted from the target gene CT to obtain the 
DCT. The mean DCT values for replicate samples were then calculated. The expression of the target gene in 
experimental samples relative to expression in control samples was then calculated using the following 
equation: 2^−[DCT (1) − DCT (2)], where DCT (1) is the mean DCT calculated for the experimental samples, and 
DCT (2) is the mean DCT calculated for the control samples. The CT values for CD44s and CD44v7/8 in the 
different cell types used for these experiments are shown in table S6. 
 
Nuclear protein extraction 
Nuclear extraction was performed according to the following protocol: Total cell lysate was resuspended in 
hypotonic buffer [20 mM tris-HCl (pH 7.4), 10mMNaCl, and 3mMMgCl2] on ice for 15min.About 10% of 
NP-40 detergent was added, and samples were vortexed. Homogenate was centrifuged for 10min at 1000 rcf 
(relative centrifugal force) at 4°C, and the supernatant (cytoplasmic fraction) was removed and frozen for 
future use. The pellet was resuspended in cell extraction buffer [100mM tris-HCl (pH 7.4), 2 mM Na3VO4, 
100mM NaCl, 1% Triton X-100, 1mM EDTA, 0.1% SDS, 1mM NaF, 0.5% deoxycholate, 20mM Na4P2O7, 
and 1% protease inhibitor cocktail (PIC)] and incubated on ice for 30 min with regular mixing at 10-min 
intervals. Samples were centrifuged at 14,000 rcf at 4°C for 30min, and the supernatant (nuclear extract) was 
transferred to fresh Eppendorfs and stored at −80°C until further use. 
 
Western blot analysis 
Total protein was extracted in radioimmunoprecipitation assay (RIPA) lysis buffer containing 1% PIC, 1% 
phenylmethylsulfonyl fluoride (PMSF), and 1% sodium orthovanadate (Santa Cruz Biotechnology). Protein 
was quantified before SDS–polyacrylamide gel electrophoresis and transfer to nitrocellulose. Membranes 
were blocked with 5% BSA/0.5% Tween 20/PBS for 1 hour (room temperature) followed by incubation with 
primary antibodies diluted in 1% BSA/0.1% Tween 20/PBS overnight at 4°C. After the washing steps, 
membranes were incubated in secondary antibodies targeting rabbit, mouse, or rat IgG (horseradish 
peroxidase conjugate) (Cell Signaling Technology; 1:5000 dilution, 1% BSA/0.1% Tween 20/PBS). 
Detection was performed using enhanced chemiluminescence reagent (GE Healthcare) and scanned using a 
C-DiGit Blot Scanner (LI-COR Biotechnology). 
 
RNA immunoprecipitation 
RIP was used to assess protein association with intronic and exonic regions of CD44 pre-mRNA. RIP 
followed by qRT-PCR using the high-capacity cDNA reverse transcription kit according to the 
manufacturer’s protocol (Applied Biosystems) was used to assess associations with U1, U2, U4, and U6 
snRNA. Specific custom primers were designed (see table S5) and purchased from Applied Biosystems. 
Cells were grown in 35-mm dishes and protein cross-linked to DNA and RNA in 0.75% v/v formaldehyde 
(10 min, room temperature) followed by the addition of glycine (125 mM v/v; 5 min, room temperature). 
Cells were harvested into 1 ml of ice-cold PBS and pelleted at 1000 rcf for 5 min before resuspension in FA 
lysis buffer [50 mM Hepes (pH 7.5), 140mMNaCl, 1mMEDTA (pH 8), 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% SDS, 1% PIC, and 1% PMSF]. Lysates were sonicated to shear DNA to fragments of 
~1200 to 1500 bp (two cycles, 15 s on/60 s off, high frequency) and centrifuged for 30 s, 5000 rcf at 4°C. 
Supernatant was transferred to new Eppendorf tubes, and 50 ml was removed for use as an input sample. A 
known volume of 25 mg of protein in RIPA buffer was immunoprecipitated (IP) using antibodies 
recognizing HYAL2, SRSF2, or SRSF5, linked sheep anti-rabbit Dynabeads (Invitrogen; pre-absorbed with 
sonicated single-stranded herring sperm DNA). IP was completed with an overnight rotating incubation at 
4°C. The bead complexes were centrifuged for 1 min at 2000 rcf, and the supernatant was removed. Beads 
were washed with wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA (pH 8), 150 mM NaCl, 
20mMTrizma base (pH 8)] three times and once with final wash buffer (wash buffer containing 500 mM 
NaCl). Protein DNA was eluted with elution buffer (1% SDS, 100 mM NaHCO3) at room temperature for 1 
hour with continuous rotation. For RIP analysis, nuclear extraction was performed before sonication, and the 
IP eluate immediately underwent RNA purification using TRI-reagent followed by DNase I treatment 
(according to the manufacturer’s protocol; New England Biolabs) to remove gDNA contamination. qRT-
PCR, using the ViiA7 real-time qPCR system from Applied Biosystems, was used to assess protein-RNA 
associations.  
 
Co-immunoprecipitation 
A known volume of 25 mg of protein from nuclear extracts in complete cell extraction buffer was IP using 
antibodies specific for HYAL2, linked to sheep anti-rabbit Dynabeads (Invitrogen). IP was completed with 
an overnight rotating incubation at 4°C. The bead complexes were centrifuged for 1 min at 2000 rcf, and the 
supernatant was removed. Beads were washed with 0.1% BSA-PBS and eluted in sample loading buffer by 
boiling the sample for 5 min before subsequent Western blotting or MS analysis. 
 
Identification of putative HYAL2-interacting proteins 
Co-IP eluates were loading into and run down 1.5-mm 7.5% polyacrylamide gels using 1D electrophoresis 
(1DE). Gel plugs were manually excised, and peptides were recovered after trypsin [6.25 ng/ml in 25 mM 
NH4HCO3, 37°C, 3 hours; sequencing grade modified trypsin from Promega digestion using a modified 
version of the method of Shevchenko et al. (31)]. The dried peptides were resuspended in 50% (v/v) 
acetonitrile in 0.1% (v/v) trifluoroacetic acid (TFA; 5 ml) for MS analysis, and a 10% aliquot was spotted 
onto a 384-wellMS plate. The samples were allowed to dry and were then overlaid with a-cyano-4-
hydroxycinnamic acid [Sigma-Aldrich; 0.5 ml of 5 mg/ml in 50% (v/v) acetonitrile and 0.1% (v/v) TFA]. 
MS was performed using a 4800 matrix-assisted laser desorption/ionization (MALDI) TOF/TOF mass 
spectrometer (Applied Biosystems) with a 200-Hz solid-state laser operating at 355 nm. MALDI mass 
spectra and subsequent MS/MS spectra of the eight most abundant MALDI peaks were obtained after 
routine calibration. Peaks were stringently selected and were analyzed with the strongest peak first. 
Identification queries were performed using the MASCOT Database search engine v2.1 (Matrix Science 
Ltd) (Perkins et al.) (32) embedded into Global Proteome Server Explorer software v3.6 (Applied 
Biosystems) on the Swiss-Prot database (download date, 09 January 2013) or the TrEMBL database 
(download date, 28 June 2011). Searches were restricted to human taxonomy with trypsin specificity (one 
missed cleavage allowed), and the tolerances were set for peptide identification searches at 50 parts per 
million for MS. One putative ID and UniProtKB (UniProt Consortium) entry is shown for each individual 
gel plug taken.  
 
In silico analysis 
Intronic sequences flanking exons encoding CD44v7 (exon 11) and CD44v8 (exon 12) were screened for 
putative exonic splice enhancer, exonic splice silencer, and splicing factor recognition sites using ESEfinder 
v3.0 (Cold Spring Harbor Laboratory) and Human Splicing Finder v3.0 (Aix-Marseille University). HYAL2 
protein domain prediction and motif recognition were analyzed using multiple ExPASy bioinformatics 
resource portal and proteomic tools (SIB Swiss Institute of Bioinformatics) and the InterPro v59 tool 
(EMBL-EBI).  
 
Statistical analysis 
For all data displayed in graphs, with two independent variable groupings, two-way analysis of variance 
(ANOVA) was used, followed by Bonferroni’s multiple comparisons and post hoc Tukey’s test. Graphical 
data are means ± SE of three independent experiments. All data were analyzed using GraphPad Prism v6. *P 
≤ 0.05, **P ≤ 0.01, and ***P ≤0.001 were considered statistically significant. 
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Fig. S4. SRSF2 RIP. 
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Table S2. Threshold scores for SR proteins (CD44 exons 11 and 12) derived from in silico analysis. 
Table S3. Individual protein IDs from nuclear HYAL2 coimmunoprecipitation. 
Table S4. In silico analysis of HYAL2 splice factor binding site thresholds. 
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